NIH Considers Guidelines for CAR-T therapy: Report from Recombinant DNA Advisory Committee Reporter: Stephen J. Williams, Ph.D. UPDATED 5/27/2024 The practice of pharmacovigilence, both premarketing and postmarketing, has very well defined best practices concerning most small molecule drugs and even medical devices.  However, for many cell based therapies and many gene based therapies, often still … Continue reading NIH Considers Guidelines for CAR-T therapy: Report from Recombinant DNA Advisory Committee